Heart rate-lowering drug improves exercise capacity in patients with stable angina

October 30, 2008

Results from a late-breaking clinical trial, presented at the 2008 Canadian Cardiology Congress (CCC) in Toronto, show for the first time that combining the pure heart rate reduction medication ivabradine to current treatments of patients with stable angina improves their exercise capacity.

The study involved almost 900 patients from Canada and internationally with documented coronary artery disease and a history of stable angina. The objective was to determine if treatment with ivabradine could improve exercise capacity in these patients beyond what was previously achieved with standard treatments. Patients received either ivabradine 5 mg bid for two months (increased to 7.5 mg bid in 87.5 percent of patients for an additional two months) or placebo for four months in addition to their current beta blocker background therapy (atenolol 50 mg daily).

"Our findings confirm that adding ivabradine over and above the standard of care achieves increases exercise tolerance," said Dr. Jean-Claude Tardif, the study's lead investigator, a professor of medicine at the Université de Montréal and director of the Montreal Heart Institute Research Centre.

"For patients who have stable angina the results are very encouraging, particularly because of tolerability concerns with higher doses of beta blockers. As a result patients are often not achieving optimal heart rate reduction on standard therapy alone," adds Dr. Tardif.

An analysis of the data from treadmill exercise tests shows that patients who were treated with ivabradine in addition to a beta blocker (n=441) demonstrated a threefold improvement in total exercise duration at four months compared to those being treated with standard doses of beta blocker alone.

After four months of treatment, the ivabradine and beta blocker combination was associated with a mean heart rate reduction of nine beats per minute (bpm) compared to one bpm in patients remaining on beta blockers alone. Patients receiving the ivabradine and beta blocker combination also had considerable improvements in symptoms and ischemia as measured by time to limiting angina, time to angina onset, and time to 1-mm ST-segment depression.

Ivabradine is not yet available for clinical use in Canada.

Source: University of Montreal


Rank 4 /5 (1 vote)
Relevant PhysicsForums posts

More news stories

Study finds that anti-diabetic medication can prevent the long-term effects of maternal obesity

In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in Dallas, Texas, researchers will report findings that show that short therapy with the anti-diabetic medication ...

Medicine & Health / Health

created 20 hours ago | popularity 5 / 5 (1) | comments 1

FDA-approved drug rapidly clears amyloid from the brain, reverses Alzheimer's symptoms in mice

Neuroscientists at Case Western Reserve University School of Medicine have made a dramatic breakthrough in their efforts to find a cure for Alzheimer's disease. The researchers' findings, published in the journal Science, show t ...

Medicine & Health / Neuroscience

created Feb 09, 2012 | popularity 4.9 / 5 (51) | comments 20 | with audio podcast

Steroid injections prove effective in treatment of lumbar disc herniations

The use of epidural steroid injections may be a more efficient treatment option for lumbar disc herniations, according to research presented today at the American Orthopaedic Society for Sports Medicine's Specialty Day in ...

Medicine & Health / Health

created 20 hours ago | popularity 5 / 5 (1) | comments 0

Amateur football players not always keen on returning to play after ACL injuries

Despite the known success rates of reconstructive Anterior Cruciate Ligament (ACL) surgery, the number of high school and collegiate football players returning to play may not be as high as anticipated, say researchers presenting ...

Medicine & Health / Health

created 20 hours ago | popularity not rated yet | comments 0

Teen school drop-outs three times as likely to be on benefits in later life

Teen school drop-outs are almost three times as likely to be on benefits in later life as their peers who complete their schooling, indicates research published online in the Journal of Epidemiology and Community Health.

Medicine & Health / Health

created Feb 06, 2012 | popularity not rated yet | comments 11


Latin America mining boom clashes with conservation

Latin America is experiencing a mining boom as prices rise fuelled by a hike in global demand, but the region is also being hit by a wave of violent protests, strikes and rallies by environmentalists.

Love a click away in Indonesia's Twitter Republic

He was a geeky kid from Yogyakarta, she a glamorous city girl in Jakarta. In a country with one of the world's most vibrant social networking scenes they fell in love on Twitter.

Walney offshore wind farm is world's biggest (for now)

(PhysOrg.com) -- The Walney wind farm on the Irish Sea--characterized by high tides, waves and windy weather--officially opened this week. The farm is treated in the press as a very big deal as the Walney ...

GPS court ruling leaves US phone tracking unclear

A US Supreme Court decision requiring a warrant to place a GPS device on the car of a criminal suspect leaves unresolved the bigger issue of police tracking using mobile phones, legal experts say.

Europeans protest controversial Internet pact

Tens of thousands of people marched in protests in more than a dozen European cities Saturday against a controversial anti-online piracy pact that critics say could curtail Internet freedom.

Europe stakes billion-dollar bet on new rocket

A pencil-slim rocket is scheduled to lift into space from South America on Monday, carrying a billion-dollar bet that Europe can grab a juicy slice of the market to place satellites in low orbit.